Pin Therapeutics is a biotechnology company dedicated to developing novel E3 ligases and molecular glue degraders for the treatment of solid tumors and hematologic cancers. Our lead program, PIN-5018, a first-in-class CK1α-selective molecular glue degrader, is currently in a Phase 1a clinical study in Korea and is being developed for adenoid cystic carcinoma (ACC), castration-resistant prostate cancer (CRPC), and colorectal cancer (CRC).

We have also established PinMARS, a proprietary E3 ligase platform built on Ligase 2, a novel E3 ligase with extremely low expression and activity in heme and immune lineage cells - distinct from commonly used ligases such as CRBN or VHL. By leveraging this heme/immune-sparing property, we aim to differentiate both our target-selection and indication strategy from conventional CRBN/VHL-based approaches. Using Ligase 2, we are currently advancing the development of an oral pan-KRas degrader.

*NO SERVICE PROVIDER REQUESTS